Regarding human prostate cancer, a very interesting study showed that Apigenin was able to suppress EMT either in vitro or in vivo in a dose and time-dependent manner by targeting SPARC/osteonectin, cwcv, and kazal-like domains proteoglycan 1 (SPOCK1)-snail/slug axis [41]. Here, SPARC is linked to prostate cancer.